bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.08.19.608540

Identifiability of heterogeneous phenotype adaptation from low-cell-count experiments and a stochastic model

Abstract

Phenotypic plasticity contributes significantly to treatment failure in many cancers. Despite the increased prevalence of experimental studies that interrogate this phenomenon, there remains a lack of applicable quantitative tools to characterise data, and importantly to distinguish between resistance as a discrete phenotype and a continuous distribution of phenotypes. To address this, we develop a stochastic individual-based model of plastic phenotype adaptation through a continuously-structured phenotype space in low-cell-count proliferation assays. That our model corresponds probabilistically to common partial differential equation models of resistance allows us to formulate a likelihood that captures the intrinsic noise ubiquitous to such experiments. We apply our framework to assess the identifiability of key model parameters in several population-level data collection regimes; in particular, parameters relating to the adaptation velocity and cell-to-cell heterogeneity. Significantly, we find that cell-to-cell heterogeneity is practically non-identifiable from both cell count and proliferation marker data, implying that population-level behaviours may be well characterised by homogeneous ordinary differential equation models. Additionally, we demonstrate that population-level data are insufficient to distinguish resistance as a discrete phenotype from a continuous distribution of phenotypes. Our results inform the design of both future experiments and future quantitative analyses that probe phenotypic plasticity in cancer. Author SummaryMany cancers adaptively and reversibly develop resistance to treatment, adding complexity to predictive model development and, by extension, treatment design. While so-called drug challenge experiments are now commonly employed to interrogate phenotypic plasticity, there are very few quantitative tools available to interpret the biological data that arises. In particular, it remains unclear what is needed from drug challenge experiments in order to identify the phenotypic structure of a population that responds adaptively to treatment. In this work, we develop a new individual-level mathematical model of phenotypic plasticity in parallel with a structured model calibration process. Applying our framework to various existing and potential experimental designs reveals that experiments that yield only population-level data cannot distinguish between drug resistance as a distinct cell state, or drug resistance as a continuum of cell states. Consequentially, at the population-level, we demonstrate that common mathematical models that assume a set of distinct cell states can characterise the behaviour of cell populations that, in actuality, respond through a continuum of states. Importantly, our results shed light on both the mathematical models and experiments required to capture phenotypic plasticity in cancer.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Browning, A. P., Crossley, R. M., Villa, C., Maini, P. K., Jenner, A. L., Cassidy, T., Hamis, S.. 2024-08-19. Identifiability of heterogeneous phenotype adaptation from low-cell-count experiments and a stochastic model. https://doi.org/10.1101/2024.08.19.608540

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗